Main Content

SK News

SK News

Fast and Accurate SK News

SK news
SK chemicals SK chemicals Agreed with Global NPO to Co-develop Next Generation Vaccine for Gastroenteritis in Children


- Active developing next generation rotavirus vaccine
- PATH will transfer its rotavirus vaccine technology in the second phase of clinical trials to SK chemicals
- Two companies will execute the third phase of clinical trials and global license together…Planning production of specimen and mass production at L HOUSE

SK chemicals is expanding its global business territory with its advanced vaccine R&D technologies and production capability.

SK chemicals announced that the company and global nonprofit organization (NPO) Program for Appropriate Technology in Health (PATH) signed an agreement for developing new rotavirus vaccine. 

This agreement is aiming to transfer PATH’s rotavirus vaccine technology into SK chemicals, develop process together for commercial production, and acquire global licenses. It also targets vaccine provision to underdeveloped countries for low prices.  

As soon as the agreement is completed, PATH will transfer its rotavirus vaccine technology to SK chemicals. Currently its rotavirus vaccine technology is in the second phase of clinical trials. After that, SK chemicals will develop and produce a specimen for clinical trial at L HOUSE (vaccine production facility) located in Andong, Korea and provide it to PATH for future clinical trials. After completing clinical trials and global license, SK chemicals will take charge of commercial production.

In addition, the two companies will review PQ certification from WHO in order to provide the vaccine to underdeveloped countries.

Park Man-Hoon, CEO of SK chemicals, said, “The first partnership with PATH will contribute to expanding SK chemicals’ vaccine pipeline. We are developing typhoid vaccine with other global NPO in order to support underdeveloped countries.”

Meanwhile, rotavirus is one of the biggest reasons for infant death, every year more than 2 million people are hospitalized because of rotavirus enteritis, and around 210,000 people die, according to WHO.

In particular, the death toll is concentrated in underdeveloped countries, especially in Africa where it is hard to get vaccinated because of insufficient infrastructure and transportation. 

Previous, Next List
Previous SK hynix SK hynix Developed World’s Fastest Next Generation Graphics DRAM 4/25/2017
Next SK networks Chairman Choi Shin-Won Receiving the First Global Philanthropy Award “Amazin~!!” World’s Focus on Chairman Choi’s Sharing Leadership 5/15/2017